BioCard™
COVID-19 BioCard™
3-minute immunity testing at the point of care, or laboratory clinic
The COVID-19 BioCard™ was a world-first innovation, the first to detect spike antibodies whilst providing measured IgG antibody concentrations in just 3 minutes. With >99.5% accuracy the BioCard™ brings a giant leap beyond traditional lateral flow tests which are limited to only a basic positive/negative result with varied reproducibility.
An unparalleled accuracy combined with optimised biochemistries able to detect precisely the key analyte enabled the BioCard™ to become the tool which cracked the enigma of covid-19 immunity.
Unlike common POC rapid tests, BioCard™ gives quantitative antibody levels, directly correlating with protective immunity. This allows healthcare providers to assess vaccine response, determine natural immunity, and track antibody decline without lab delays or equipment.
Monitoring individual immunity enables resources to be sharply focussed according to established clinical need, gone is arbitrary age or dates with boosters given to the wrong people.
Increasing vaccine uptake, by inviting people to an immunity health check, which takes just moments, ensures vaccine uptake is much more likely accepted. A simple step, which saves valuable resources and whilst improving the desired outcome of true immunisation, with sustained herd immunity, at less cost than unmanaged arbitrary vaccinations.
Key Features:
- Quantitative spike specific IgG antibody monitoring.
- Faster than lateral flow, more accurate than ELISA/CLIA.
- No equipment required.
- Perfect for immunity monitoring and vaccine follow-up.
- Ideal of improving efficacy during vaccine clinical trials.
The BioCard™ platform is already proven to work with new viral variants and can be adapted to new biological threats within 24 hours of receiving target material.
